Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis

Parasitology International

Volumn 58, Issue 4, 2009, Pages 359-366

  Nagill, Rajeev ^a   Mahajan, Raman ^a   Sharma, Meenakshi ^a   Kaur, Sukhbir ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Antigens; Autoclaved Leishmania donovani; Heat killed Leishmania donovani; Immunization; Vaccine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LEISHMANIA VACCINE; PARASITE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; AUTOCLAVE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DOWN REGULATION; DRUG MECHANISM; EXPERIMENTAL INFECTION; FEMALE; HEAT TREATMENT; HUMORAL IMMUNITY; IMMUNOSTIMULATION; LEISHMANIA DONOVANI; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; QUANTITATIVE ASSAY; REPEATED DRUG DOSE; SKIN LEISHMANIASIS; SPLEEN; SPLEEN CELL; TH1 CELL; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYTOKINES; IMMUNIZATION; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; STERILIZATION; TH1 CELLS; VACCINES, INACTIVATED;

LEISHMANIA DONOVANI; MUS;

EID: 70349732919     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parint.2009.07.008     Document Type: Article

References (59)

1. Piscopo T.V., and Azzopardi C.M. Leishmaniasis. Postgrad Med J 83 (2006) 649-657
2. Alvar J., Canavate C., Gutierrez-Solar B., Jimenez M., Laguna F., Lopez-Velez R., et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10 2 (1997) 298-319
3. World Health Organization-TDR. The TDR fifteenth programme report. Research progress 1999-2000. New and improved tools. 2003; www.who.int/tdr/research/progress9900/tools/vdr.htm.
4. Desjeux P. Global control and Leishmania HIV co-infection. Clin Dermatol 17 3 (1999) 317-325
5. Dumonteil E, McMahon-Pratt D, Price VL. Report of the fourth TDR/IDRI meeting on second generation vaccines against leishmaniaisis. UNDP/EWorld Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR). 2001;TDR/PRD/Leish/Vac/01.1.
6. da Silva V., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto RN). Vaccine 19 9-10 (2000) 1082-1092
7. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Gonc ̧alo do Amarante RN). Vaccine 20 27-28 (2002) 3277-3284
8. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
9. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., and Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district I.R. Iran. Vaccine 22 29-30 (2004) 4097-4100
10. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 22 (2005) 2825-2840
11. ® vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 40 (2005) 4805-4810
12. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23 28 (2005) 3716-3725
13. ®) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24 13 (2006) 2423-2431
14. Lemesre J.L., Holzmuller P., Goncalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomized efficacy field trial. Vaccine 25 21 (2007) 4223-4234
15. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A., et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine. Vaccine 25 33 (2007) 6176-6190
16. Jeronimo S.M., Higgs E., Vedvick T., Mann B.J., Jernigan J., Petri Jr. W.A., et al. Identification of Leishmania chagasi antigens recognized by human lymphocytes. J Infect Dis 172 4 (1995) 1055-1060
17. Ravindran R., and Ali N. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. Curr Mol Med 4 (2004) 697-709
18. Mayrink W., Genaro O., Silva J.C., da Costa R.T., Tafuri W.L., Toledo V.P., et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem Inst Oswaldo Cruz 91 6 (1996) 695-697
19. Dube A., Sharma P., Srivastava J.K., Misra A., and Katiyar J.C. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 116 3 (1998) 219-221
20. Gicheru M.M., Olobo J.O., Anjili C.O., Orago A.S., Modabber F., and Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 69 1 (2001) 245-251
21. Misra A., Dube A., Srivastava B., Sharma P., Srivastava J.K., and Katiyar J.C. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania with BCG. Vaccine 19 25-26 (2001) 3485-3492
22. Amaral V.F., Teva A., Oliviera-Neto M.P., Silva A.J., Pereira M.S., Cupolillo E., et al. Study of the safety, immunogenicity and efficacy of autoclaved and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem Inst Oswaldo Cruz 97 7 (2002) 1041-1048
23. Michel M.Y., Fathy F.M., Hegazy E.H., Hussein E.D., Eissa M.M., and Said D.E. The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis. J Egypt Soc Parasitol 36 1 (2006) 159-176
24. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., de Oliveira Aguiar-Soares R.D., et al. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine 25 (2007) 7674-7686
25. Giunchetti R.C., Reis A.B., da Silveira-Lemos D., Martins-Filho O.A., Correa-Oliveira R., Bethony J., et al. Antigenicity of whole parasite vaccine as promising candidate against canine leishmaniasis. Res Vet Sci 85 (2008) 106-112
26. Srivastava J.K., Misra A., Sharma P., Srivastava B., Naik S., and Dube A. Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis. Parasitology 127 2 (2003) 107-114
27. Mayrink W., Williams P., da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., et al. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito Santo, Brazil. Ann Trop Med Parasitol 79 3 (1985) 259-269
28. Castes M., Blackwell J., Trujillo D., Formica S., Cabrera M., Zorrilla G., et al. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG I. Skin-test reactivity T-cell proliferation and interferon-γ production. Vaccine 12 11 (1994) 1041-1051
29. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., and Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population. Safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 177 5 (1998) 1352-1357
30. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Ghassemi R.L., et al. A randomised, double-blind controlled trial of a killed Leishmania major plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17 5 (1998) 466-472
31. Khalil E.A.G., El-Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. Lancet 356 (2000) 1565-1569
32. Sharifi I., Fekri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic leishmaniasis in Bam, Iran. Lancet 351 9115 (1998) 1540-1543
33. Satti I.N., Osman H.Y., Daifalla N.S., Younis S.A., Khalil E.A., Zijlstra E.E., et al. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 19 15-16 (2001) 2100-2106
34. Convit J., Castellanos P.L., Rondon A., Pinardi M.E., Ulrich M., Castes M., et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1 8530 (1987) 401-405
35. Cabrera M., Blackwell J.M., Castes M., Trujillo D., Convit J., and Shaw M.A. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 22 2 (2000) 73-79
36. Convit J., Ulrich M., Zerpa O., Borges R., Aranzazu N., Valera M., et al. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg 97 4 (2003) 469-472
37. Armijos R.X., Weigel M.M., Romero L., Garcia V., and Salazar J. Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?. J Infect Dis 187 12 (2003) 1959-1961
38. Noazin S., Modabber F., Khamesipour A., Smith P.G., Moulton L.H., Nasseri K., et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26 52 (2008) 6759-6767
39. Convit J., Ulrich M., Polegre M.A., Avila A., Rodriguez N., Mazzedo M.I., et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 99 1 (2004) 57-62
40. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho, Roatt B.M., de Oliveira Aguiar-Soares R.D., et al. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 26 5 (2008) 623-638
41. Goel A., Vohra H., and Varshney G.C. Strain-specific recognition of live Leishmania donovani promastigotes by homologous antiserum raised against a crude membrane fraction of infected macrophages. Parasitol Res 85 1 (1999) 19-24
42. Lowry O.H., Rosenburg N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
43. Bradley D.J., and Kirkley J. Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice. Clin Exp Immunol 30 1 (1977) 119-129
44. Kaur S., Kaur T., Garg N., Mukherjee S., Raina P., and Athokpam V. Effect of dose and route of inoculation on the generation of CD4+ Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 103 6 (2008) 1413-1419
45. Mitchell G.F., and Handman E. Heterologous protection in murine cutaneous leishmaniasis. Immunol Cell Biol 65 5 (1987) 387-392
46. Nurit R., and Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J Immunol 150 (1993) 2322-2331
47. Gicheru M.M., Olobo J.O., and Anjili C.O. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease. Exp Parasitol 85 2 (1997) 109-116
48. Ghalib H., and Modabber F. Consultation meeting on the development of therapeutic vaccines for post kala-azar dermal leishmaniasis. Kinetoplastid Biol Dis 6 (2007) 7-20
49. Musa A.M., Khalil E.A., Mahgoub F.A., Elgawi S.H., Modabber F., Elkadaru A.E., et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 102 1 (2008) 58-63
50. Melby P.C., Yang Y.Z., Cheng J., and Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 66 1 (1998) 18-27
51. Bretscher P.A., Wei G., Menon J.N., and Bielefeldt-Ohmann H. Establishment of cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257 5069 (1992) 539-542
52. Dube A., Srivastava J.K., Sharma P., Chaturvedi A., Katiyar J.C., and Naik S. Leishmania donovani: cellular and humoral immune responses in Indian langur monkeys Presbytus entellus. Acta Trop 73 1 (1999) 37-48
53. Carvalho E.M., Badaro R., Reed S.G., Jones T.C., and Johnson Jr. W.D. Absence of gamma-interferon and interleukin-2 production during active visceral leishmaniasis. J Clin Invest 76 6 (1985) 2066-2069
54. Carvalho E.M., Bacellar O., Brownell C., Regis T., Coffman R.L., and Reed S.G. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152 12 (1994) 5949-5956
55. Squires K.E., Schreiber R.D., McElrath M.J., Rubin B.Y., Anderson S.L., and Murray H.W. Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. J Immunol 143 12 (1989) 4244-4249
56. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., and Murray H.W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 62 3 (1994) 1058-1063
57. Murray H.W. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis 175 6 (1997) 1477-1479
58. Stober C.B., Lange U.G., Roberts M.T., Alcam A., and Blackwell J.M. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 175 4 (2005) 2517-2524
59. Roberts M.T., Stober C.B., McKenzie A.N., and Blackwell J.M. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect Immun 73 11 (2005) 7620-7628